BMO-MRW best predictor of progression

Article

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a new study.

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a study published in Clinical Ophthalmology.

Japanese researchers examined the association between structural parameters of the optic nerve head and glaucomatous visual field indices in a total of 57 eyes in 33 patients with glaucomatous optic neuropathy.

The researchers measured the patients' visual fields, peripapillary retinal nerve fibre layer thickness (RNFL-T), BMO-MRW, and rim area. They then calculated Spearman's rank correlation coefficients between the threshold of visual sensitivity or total deviation of visual field and between the structural parameters as well as calculated RNFL-T and BMO-MRW volumes (each length multiplied by rim area).

They found that the threshold of visual sensitivity had the following correlation coefficients:

  • 0.23 with global sector of RNFL-T
  • 0.32 with BMO-MRW
  • 0.14 with rim area
  • 0.21 with RNFL-T volume
  • 0.26 with BMO-MRW volume

The correlation coefficients for each parameter with total deviation of visual field were as follows:

  • 0.22 with global sector of RNFL-T
  • 0.33 with BMO-MRW
  • 0.28 with rim area
  • 0.36 with RNFL-T volume
  • 0.37 with BMO-MRW volume

"Our study data confirm that total deviation was more strongly correlated with RNFL-T volume and BMO-MRW volume than with BMO-MRW. However, BMO-MRW appeared to be the best predictor of both the threshold of visual sensitivity and total deviation of visual field, and may be more useful for detecting and evaluating the progression of glaucoma," the researchers wrote.

To access the full article, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.